Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0

SpringWorks Therapeutics (SWTX) shares ended the last trading session 6% higher at $41.20. The jump came on an impressive volume with a higher-than-average number of shares …

6%
OFF

Strength Seen In SpringWorks Therapeutics (SWTX): Can Its 6.0

2 weeks from now

SpringWorks Therapeutics (SWTX) shares ended the last trading session 6% higher at $41.20. The jump came on an impressive volume with a higher-than-average number of shares …

msn.com

3%
OFF

SpringWorks Therapeutics Jumps Amid Takeover Speculation - MSN

2 weeks from now

SpringWorks Therapeutics (NASDAQ:SWTX) advanced 6.3% amid takeover speculation. The biotech firm is said to be at the center of renewed takeover speculation, according to a …

msn.com

0%
OFF

SWTX Stock Price | SpringWorks Therapeutics Inc. Stock Quote …

2 weeks from now

3 days ago · Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? Jan. 8, 2025 at 3:36 a.m. ET on Zacks.com SpringWorks Therapeutics price …

marketwatch.com

0%
OFF

SpringWorks Therapeutics Stock Price | SWTX Stock Quote, News, …

2 weeks from now

5 days ago · Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? Historical Prices for SpringWorks Therapeutics Feb. 04 2021 Mar. 05 2021

businessinsider.com

10%
OFF

Analyst Estimates: Here's What Brokers Think Of SpringWorks ...

2 weeks from now

Nov 15, 2024 · Shareholders of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) will be pleased this week, given that the stock price is up 10% to US$36.55 following its latest quarterly …

yahoo.com

0%
OFF

SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80 …

2 weeks from now

Aug 21, 2024 · The biotech company reported 0% EPS growth in the latest quarterly report, while sales growth came in at -100%. SpringWorks Therapeutics stock earns the No. 169 rank …

investors.com

0%
OFF

Strong ‘Buy’ Rating For SpringWorks Therapeutics ... - Markets …

2 weeks from now

Nov 16, 2023 · Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? Zacks 23h SpringWorks Therapeutics price target lowered to $55 from …

businessinsider.com

$55
OFF

SpringWorks Therapeutics Price Target Lowered To $55 From $58 At …

2 weeks from now

Jan 7, 2025 · BofA lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $55 from $58 and keeps a Buy rating on the shares. While political and rate uncertainty continues …

businessinsider.com

6%
OFF

Strength Seen In SpringWorks Therapeutics (SWTX): Can Its 6.0

2 weeks from now

Jan 8, 2025 · SpringWorks Therapeutics (SWTX Quick Quote SWTX - Free Report) shares ended the last trading session 6% higher at $41.20. The jump came on an impressive volume with a …

zacks.com

40%
OFF

SpringWorks (SWTX) Rises More Than 40% In A Year: Here's Why

2 weeks from now

Jul 12, 2024 · SpringWorks' (SWTX) Ogsiveo is the first drug approved by the FDA to treat desmoid tumors. The company's efforts to develop its pipeline candidate, mirdametinib, for …

yahoo.com

40%
OFF

SpringWorks (SWTX) Rises More Than 40% In A Year: Here's Why

2 weeks from now

Jul 12, 2024 · You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for Acrivon Therapeutics’ 2024 loss per share have narrowed …

nasdaq.com

$1.68
OFF

SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down

2 weeks from now

2 days ago · You can see the complete list of today’s Zacks #1 Rank stocks here. In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.68 to $1.48 …

zacks.com

6%
OFF

Strength Seen In SpringWorks Therapeutics (SWTX): Can Its 6.0

2 weeks from now

Jan 8, 2025 · SpringWorks Therapeutics (SWTX) shares ended the last trading session 6% higher at $41.20. The jump came on an impressive volume with a higher-than-average number of …

yahoo.com

0%
OFF

Strength Seen In SpringWorks Therapeutics (SWTX): Can Its 6.0

2 weeks from now

Jan 8, 2025 · Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?

wallstreetwaves.com

$78
OFF

SpringWorks Therapeutics Price Target Lowered To $78 From $80 At …

2 weeks from now

Jan 8, 2025 · Try Now>> See Insiders’ Hot Stock. Guggenheim analyst Michael Schmidt lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $78 from $80 and keeps a Buy …

yahoo.com

19%
OFF

SpringWorks Catapults 19% On A 'Watershed Moment' In Cancer …

2 weeks from now

Nov 28, 2023 · Related news Stocks With Rising Relative Strength: SpringWorks Therapeutics. 9/09/2024 SpringWorks Therapeutics shows rising price performance, earning an upgrade to …

investors.com

42%
OFF

SpringWorks Therapeutics (SWTX) Competitors And Alternatives …

2 weeks from now

Jan 8, 2025 · Qiagen received 149 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. However, 70.42% of users gave SpringWorks Therapeutics an …

marketbeat.com

FAQs about Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0 Coupon?

Can SpringWorks Therapeutics (SWTX)'s 6% jump turn into more strength?

Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? SpringWorks Therapeutics (SWTX) shares ended the last trading session 6% higher at $41.20. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. ...

Should you buy SpringWorks Therapeutics Inc (SWTX) stock?

Goldman Sachs analyst Corinne Jenkins has maintained their bullish stance on SWTX stock, giving a Buy rating on November 9. Corinne Jenkins’ “Buy” rating on Springworks Therapeutics Inc.’s stock (SWTX) is underpinned by several factors. ...

Where is SpringWorks Therapeutics Inc headquartered?

Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT. SWTX | Complete SpringWorks Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ...

Is SpringWorks Therapeutics (SPR) a good stock to buy?

SpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. According to analysts' consensus price target of $59.40, SpringWorks Therapeutics has a forecasted upside of 148.0% from its current price of $23.95. ...

Will SpringWorks Therapeutics' growth accelerate?

It's clear from the latest estimates that SpringWorks Therapeutics' rate of growth is expected to accelerate meaningfully, with the forecast 125% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 52% p.a. over the past five years. ...

How does SpringWorks Therapeutics perform in Q3 2024?

SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and growing sales, though they remain unprofitable, with a net loss of $53.5 million in Q3 2024. ...